Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL431328 | 0.80 | MAPT (0.48) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL5583739 | 0.77 | ERN1 (0.51) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL5615222 | 0.74 | GABRA1 (0.57) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL1814299 | 0.74 | ALDH1A1 (0.47) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL31106423 | 0.74 | KDM4E (0.68) | KMT2AMAPTKDM4EALDH1A1GAA | |
| SCHEMBL6892279 | 0.74 | KDM4E (0.68) | KMT2AMAPTKDM4EALDH1A1GAA | |
| SCHEMBL7212101 | 0.74 | LOXL2 (0.58) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL11190488 | 0.73 | CDK1 (0.46) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL5583660 | 0.73 | KDM4E (0.41) | MAPTKDM4EALDH1A1GAALMNA | |
| SCHEMBL14456319 | 0.73 | KDM4E (0.39) | MEN1KMT2AMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100384849-C | Quinoline 3-Aminochroman Derivatives | WYETH CORP (US) | 2008-04-30 | — | — | CN | disclosed |
| US-20070191417-A1 | QUINOLINE 3-AMINO CHROMAN DERIVATIVES | HATZENBUHLER NICOLE T | 2007-08-16 | — | — | US | disclosed |
| US-20070191417-A1 | QUINOLINE 3-AMINO CHROMAN DERIVATIVES | HATZENBUHLER NICOLE T | 2007-08-16 | — | — | US | disclosed |
| US-20070191417-A1 | QUINOLINE 3-AMINO CHROMAN DERIVATIVES | HATZENBUHLER NICOLE T | 2007-08-16 | — | — | US | disclosed |
| US-7227023-B2 | Quinoline 3-amino chroman derivatives | WYETH (US) | 2007-06-05 | — | — | US | disclosed |
| US-7227023-B2 | Quinoline 3-amino chroman derivatives | WYETH (US) | 2007-06-05 | — | — | US | disclosed |
| US-7227023-B2 | Quinoline 3-amino chroman derivatives | WYETH (US) | 2007-06-05 | — | — | US | disclosed |
| CN-1809574-A | Quinoline 3-amino chroman derivatives | WYETH CORP (US) | 2006-07-26 | — | — | CN | disclosed |
| EP-1638976-A1 | QUINOLINE 3-AMINO CHROMAN DERIVATIVES | Wyeth (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050004157-A1 | Quinoline 3-amino chroman derivatives | WYETH | 2005-01-06 | — | — | US | disclosed |
| WO-2004099214-A1 | QUINOLINE 3-AMINO CHROMAN DERIVATIVES | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
| EP-1432694-A1 | STEREOSPECIFIC PROCESS FOR THE SYNTHESIS OF 2-YL CHROMAN DERIVATIVES | Wyeth (US) | 2004-06-30 | — | — | EP | disclosed |
| EP-1432695-A1 | A PROCESS FOR THE STEREOSELECTIVE SYNTHESIS OF 2-HYDROXYMETHYL-CHROMANS | Wyeth (US) | 2004-06-30 | — | — | EP | disclosed |
| US-6716998-B2 | SUCH AS (2R)-3,4-DIHYDRO-2H-CHROMEN-2-YL-METHYL-4-METHYL-BENZENESULFONATE; METATHESIS RING CLOSING POLYMERIZATION | WYETH | 2004-04-06 | — | — | US | disclosed |
| US-6700001-B2 | USEFUL AS INTERMEDIATES TO DRUGS INCLUDING THOSE TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS; STEREOSPECIFIC CYCLIZATION OF AN OPTICALLY ACTIVE PHENOL COMPOUND | WYETH | 2004-03-02 | — | — | US | disclosed |
| US-20030105342-A1 | Process for stereoselective synthesis of 2-hydroxymethyl chromans | WYETH | 2003-06-05 | — | — | US | disclosed |
| US-20030100774-A1 | Process for synthesis of 2-yl chroman derivatives | WYETH (US) | 2003-05-29 | — | — | US | disclosed |
| WO-2003031428-A1 | STEREOSPECIFIC PROCESS FOR THE SYNTHESIS OF 2-YL CHROMAN DERIVATIVES | WYETH (US) | 2003-04-17 | — | — | WO | disclosed |
| WO-2003031429-A1 | A PROCESS FOR THE STEREOSELECTIVE SYNTHESIS OF 2-HYDROXYMETHYL-CHROMANS | WYETH (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100774-A1 | Process for synthesis of 2-yl chroman derivatives | CDYL, CDY1; CDY1B, CDYL2 | MEN1 655/4885KMT2A 226/4885MAPT 4517/4885 |
| US-20030105342-A1 | Process for stereoselective synthesis of 2-hydroxymethyl chromans | CYP2S1, CYP1B1, CYP1A2 | MEN1 1599/4885KMT2A 784/4885MAPT 4787/4885 |
| US-20070191417-A1 | QUINOLINE 3-AMINO CHROMAN DERIVATIVES | HTR3C, HTR3A, HTR2C | MEN1 1748/4885KMT2A 1520/4885MAPT 1774/4885 |
| US-20050004157-A1 | Quinoline 3-amino chroman derivatives | HTR3C, HTR3A, HTR2C | MEN1 1748/4885KMT2A 1520/4885MAPT 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.